Vistin Pharma ASA
Research Vistin Pharma ASA (VISTN) on Bullrun: valuation model: 45.4% undervalued, market cap NOK 891.33M, P/E 12.0, dividend yield 5.3%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerVISTN
- ExchangeOL
- CountryNorway
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyNOK
- Valuation signal45.4% undervalued
- Market capNOK 891.33M
- P/E12.0
- Dividend yield5.3%
- Financial periodQ1 2026
- RevenueNOK 112.21M
- Net incomeNOK 21.49M
- Free cash flow-NOK 9.58M
- Gross margin64.9%
Valuation Snapshot
Bullrun's latest valuation model marks Vistin Pharma ASA as 45.4% undervalued; latest market cap is NOK 891.33M; P/E is 12.0; dividend yield is 5.3%.
Peer valuation comparison
Latest P/E is 11.96x versus a Healthcare sector median of 24.46x (51.1% below).
Latest dividend yield is 5.25% versus a Healthcare sector median of 2.11% (148.8% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | NOK 452.29M | NOK 74.76M | n/a | 66.5% | n/a | NOK 16.42M | NOK 619.00K | NOK 328.81M |
| FY2024 | NOK 429.50M | NOK 62.76M | n/a | 65.1% | n/a | NOK 12.79M | NOK 1.33M | NOK 309.53M |
| FY2023 | NOK 438.33M | NOK 45.64M | n/a | 59.7% | n/a | n/a | n/a | n/a |
| FY2022 | NOK 304.85M | -NOK 4.68M | n/a | 54.7% | n/a | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-14 | NOK 891.33M | 12.0 | 7.4% | 1.5 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 1.5 NOK, yield 5.3%.
About Vistin Pharma ASA
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, engages in the production and sale of active pharmaceutical ingredients (APIs) in Africa, Europe, Asia, and North and South America. It offers metformin HCl; metformin direct compressible; and metformin premixed with lubricant magnesium stearate for use in plain metformin immediate release tablets. The company was founded in 1969 and is based in Oslo, Norway.
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Vistin Pharma ASA overvalued or undervalued?
Bullrun's valuation model currently marks Vistin Pharma ASA as 45.4% undervalued.
What is Vistin Pharma ASA's market cap?
Vistin Pharma ASA's market capitalization is NOK 891.33M.
What is Vistin Pharma ASA's P/E ratio?
Vistin Pharma ASA's price-to-earnings (P/E) ratio is 12.0.
Does Vistin Pharma ASA pay a dividend?
Vistin Pharma ASA has a dividend yield of 5.3%.
What does Vistin Pharma ASA do?
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, engages in the production and sale of active pharmaceutical ingredients (APIs) in Africa, Europe, Asia, and North and South America. It offers metformin HCl; metformin direct compressible; and metformin premixed with lubricant magnesium stearate for use in plain metformin immediate release tablets. The company was founded in 1969 and is based in Oslo, Norway.